Trial Profile

A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ORIN 1001 (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; Colorectal cancer; HER2 negative breast cancer; HER2 positive breast cancer; Liver cancer; Male breast cancer; Mesothelioma; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Fosun Orinove

Most Recent Events

31 Dec 2024 Status changed from active, no longer recruiting to completed.
18 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
16 Jul 2023 Planned End Date changed from 30 Mar 2023 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com